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Few treatments have been introduced in recent decades
which are as effective as the modern treatment of myocar-
dial infarction, based on rapid diagnosis (often by ambu-
lance personnel, before admission to a hospital), immediate
referral for reperfusion therapy (preferably by PCI), early
discharge and subsequent intensive medical treatment for
secondary prevention. The need for immediate PCI places a
great burden on the medical staff (interventional cardiolo-
gists, nurses, technicians) of the hospital since many pro-
cedures need to be performed outside ‘normal’ working
hours. Nevertheless such treatment is offered to most pa-
tients in the Netherlands admitted with ST-segment eleva-
tion on the ECG (STEMI) because the benefits are
undisputable. Long-term follow-up of the study of reperfu-
sion therapy by the Interuniversity Cardiology Institute in
The Netherlands (ICIN) revealed that the early benefits of
reperfusion therapy were sustained during 20 years, with a
gain in life expectancy of 2.8 years [1]! The additional costs
of reperfusion therapy during the first year after hospital
admission were estimated at Dfl 7000 (€ 3200) [2], which
amounts to only Dfl 2500 (€ 1150) per life-year saved!
Further improvement of therapy for myocardial infarction
was achieved by primary PCI as developed in Zwolle [3].
Indeed, systematic application of primary PCI resulted in a
major further improvement of survival. For example, sur-
vival after 3 years of patients admitted with STEMI to the
Thoraxcentre improved from 75% in the last decade of the
previous century to 87% thereafter [4]. This represents a
48% reduction in mortality!
In this issue of the journal Soekhlal et al. report an
analysis of current treatment costs of myocardial infarction
in the Netherlands [5]. According to their calculations treat-
ment costs for STEMI including PCI are about € 5700 and
for patients with STEMI treated without PCI about € 4300.
This is a modest difference of € 1400, well worth the
benefits. Direct PCI is very cost-effective therapy. However,
to my regret, the authors do not mention these benefits and
present only costs. The authors indicate that their calcula-
tions may be used to support decision-making in health care,
but such decision-making should also take into account the
benefits of the treatment. Indeed, treatment of myocardial
infarction carries a cost, but it should be seen as investment,
an investment in health, an investment resulting in a signif-
icantly improved longevity and quality of life! Few inter-
ventions are as cost-effective as primary PCI.
Apart from the focus on costs alone, the report by
Soekhlal has several other shortcomings. First, the authors
describe four groups of patients: 8087 patients with STEMI
undergoing PCI, 6765 STEMI receiving thrombolysis, 1800
non-STEMI undergoing PCI and 9005 non-STEMI receiv-
ing thrombolysis. This must be an error! Thrombolysis is
indicated in patients with STEMI if timely direct PCI by an
experienced team is not possible, but certainly not in pa-
tients presenting without ST-segment elevation (non-
STEMI). Probably they refer to patients treated without
PCI, or ‘non-invasively’, but throughout the text thrombol-
ysis appears. Second, the reported treatment costs have a
substantial variation, from € 34 to € 870,653. Both the low,
as well as the high cost values are unusual to say the least.
This requires some discussion and explanation. Probably
this represents errors in the registration system, which
should be sorted out if decisions in health care policy are
to be based on these figures. With such extremes the means
and standard deviations presented by the authors are not
reliable and medians with 95% ranges would be more ap-
propriate. In fact, mean treatment costs of € 5201 with a
standard deviation of € 6906 implies that in about a quarter
of the cases the costs were negative, which is obviously not
true. Third, it is not clear whether the report concerns only
the costs during the first hospital admission or also follow-
up costs. The latter is suggested in the methods mentioning
‘outpatient and emergency room visits’ and in the results
mentioning ‘PCI performed in a day-care setting’, although
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this might refer to patients admitted in a smaller hospital
who are transported to a large centre for PCI and return to
the smaller hospital immediately after the procedure. In that
case it should be mentioned and the ambulance transporta-
tion costs should be included in the analysis. Finally, the
report would have been improved and medical mistakes
would have been avoided by cooperation with cardiology
experts. A sentence like ‘Because PCI procedures are not
believed to be beneficial to STEMI patients when the coro-
nary artery is damaged…. STEMI patients received fewer
PCI procedures and coronary stents than non-STEMI pa-
tients’ is not clear. In fact, in all STEMI patients the coro-
nary artery is damaged and this is specifically the indication
to perform PCI and place a stent. Furthermore PCI is indi-
cated and performed more often rather then less frequently
in STEMI than in non-STEMI, which is also evident from
table 2 in the report: 54% of STEMI patients underwent PCI
and only 17% of non-STEMI patients. Finally, the European
guidelines [6] recommend participation in a rehabilitation
program for all patients after myocardial infarction, not only
for those treated without PCI as erroneously mentioned in
the report.
Analysis of the efficacy, the costs and the efforts of
medical care is important indeed, and it is likely that future
decisions regarding allocation of scarce resources will be
based on such analyses. Proper understanding of the eco-
nomic implications of medical procedures, such as treatment
of myocardial infarction, requires close collaboration of
healthcare economists and medical scientists with a feeling
for the economic aspects of their profession. It is to be
regretted that the authors who report the treatment costs of
acute myocardial infarction and the editors of this journal
have not recognised the value of such collaboration. Never-
theless, and in spite of its shortcomings, the report supports
earlier observations about the treatment costs of myocardial
infarction [2]. Indeed direct PCI is a bit more expensive than
conventional treatment [5]. However, these costs, or rather
this investment, and the personnel efforts are well spent, to
the benefit of many patients.
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